Guggulu in classical Ayurveda

What it is

Guggulu is the oleo-gum resin that exudes from cuts made in the stem and branches of Commiphora wightii (Arnott) Bhandari, the synonym Commiphora mukul is still used in much of the literature, a small, thorny, bushy tree of the Burseraceae family native to the arid regions of India, Bangladesh, and Pakistan (Sarup et al., Scientifica 2015). The resin collects in small ducts throughout the bark; trees are tapped by incising the bark, the resin hardens, and it is collected through May–June, with a single tree yielding only a few hundred grams of dry resin per collection season (Sarup et al.). The compounds most often credited with its effects are the E- and Z-guggulsterones: genuine samples contain about 1.0–1.5% of them, alongside roughly 1% volatile oil (Sarup et al.). Gugulipid, an ethyl acetate extract of the resin, was approved in India in 1987 as a hypolipidemic drug (Brobst et al., Expert Opin Drug Metab Toxicol 2006).

The source tree itself is in trouble: C. wightii was moved from Data Deficient to Critically Endangered on the IUCN Red List of Threatened Species, driven by destructive resin tapping, and after India imposed an export ban the harvesting pressure shifted to other countries such as Pakistan (Yang et al., Pharmaceuticals 2024).

Classical properties

• Taste (rasa): bitter (Tikta), pungent (Katu)
• Qualities (guna): light (Laghu), dry (Ruksha)
• Potency (virya): warming (Ushna)
• After digestion (vipaka): pungent (Katu)
• Doshas: traditionally said to settle Kapha and Vata; may increase Pitta

Traditional use

Guggulu is one of Ayurveda's oldest resins: the Atharvaveda is the earliest recorded reference, and its actions, varieties, and indications were detailed in the Charaka Samhita, Sushruta Samhita, and the works of Vagbhata (Sarup et al.). It has been used for thousands of years for arthritis, inflammation, gout, rheumatism, obesity, and disorders of lipid metabolism (Sarup et al.). Later literature expanded its indications to osteoarthritis, rheumatoid arthritis, gout, facial paralysis, sciatica, constipation, hemorrhoids, liver disorders, cysts, cervical lymphadenitis, coronary thrombosis, anemia, diabetes, urinary calculus, skin diseases, and others (Sarup et al.).

Ayurvedic texts insist that raw guggulu must be purified (shodhana) before being incorporated into formulations. Unpurified resin is said to cause skin rashes, irregular menstruation, diarrhea, headache, and mild nausea, and very high doses are associated in the texts with liver toxicity (Sarup et al.). These are traditional claims, not clinical proof: the modern trial evidence is assessed separately below.

What research has looked at

Cholesterol (randomized controlled trial)

The strongest human evidence is a negative trial. Szapary et al. ran a double-blind, randomized, placebo-controlled trial in 103 hypercholesterolemic adults in Philadelphia: a standardized guggulipid at a standard or a high dose, taken for 8 weeks (Szapary et al., JAMA 2003). LDL cholesterol fell 5% on placebo but rose 4% on the standard dose (P=.01 vs placebo) and 5% on the high dose (P=.006): a net positive change of 9–10%. There were no significant changes in total cholesterol, HDL, triglycerides, or VLDL. Six participants on guggulipid developed a hypersensitivity rash, versus none on placebo. The authors concluded guggulipid did not improve serum cholesterol over the short term and might raise LDL (Szapary et al.).

Drug interactions (mechanistic and human data)

Guggulsterones (E and Z) activate the pregnane X receptor in both rodents and humans, which upregulates drug-metabolizing enzymes such as CYP3A4 and drug transporters: the classic mechanism by which one substance lowers blood levels of another (Brobst et al.). Through this mechanism, guggul could lower blood levels of co-administered drugs that are CYP3A4 substrates. Anyone taking prescription medicines should discuss guggulu with their doctor or pharmacist.

What the evidence does not support (yet)

No adequate human trials were identified for weight loss, diabetes, cancer, or heart-disease prevention. Traditional use in these areas is not clinical proof.

Safety notes

Short-term tolerability: in the JAMA trial, 6 of 67 guggulipid-treated participants developed a hypersensitivity rash versus none of 36 on placebo (Szapary et al.). One published case report of rhabdomyolysis exists (Medscape review): a rare signal, not proof of incidence or causality. Traditional accounts also report gastrointestinal upset and headache with unpurified resin (Sarup et al.).

During pregnancy and breastfeeding: no human safety data exist. Ayurvedic texts describe guggulu as a uterine stimulant and emmenagogue (Sarup et al.), a traditional property that is reason to avoid it in pregnancy; any use is one to discuss with a qualified practitioner.

Drug interactions: guggulsterones activate the pregnane X receptor, inducing CYP3A4 and drug transporters: a mechanism that can lower blood levels of co-administered drugs (Brobst et al.). Anyone taking prescription medicines should discuss guggulu with their doctor or pharmacist.

Human toxicity research is limited: the absence of evidence is not evidence of safety.

FAQs

Does guggulu lower cholesterol?

The best available trial, 103 US adults, 8 weeks, did not lower cholesterol: LDL rose 4–5% on guggulipid while falling 5% on placebo (Szapary et al.).

What is guggulipid?

An ethyl acetate extract of the resin, approved in India in 1987 as a hypolipidemic drug (Brobst et al.). It is the preparation used in the failed US cholesterol trial.

Does guggulu interact with medications?

Yes. It activates the pregnane X receptor and can induce CYP3A4, which can lower blood levels of co-administered drugs (Brobst et al.).

Is guggulu safe in pregnancy?

No human safety data exist, and Ayurvedic texts describe it as a uterine stimulant and emmenagogue (Sarup et al.). Avoid use in pregnancy; discuss any use with a qualified practitioner.

What are the main side effects?

In the JAMA trial, 6 of 67 guggulipid-treated participants developed a hypersensitivity rash versus none on placebo (Szapary et al.); traditional accounts also report gastrointestinal upset and headache with unpurified resin (Sarup et al.). One published case report of rhabdomyolysis exists (Medscape review).

What dose of guggulu was studied?

Swastik does not suggest amounts. The right amount depends on the person, the preparation and the product, so check with a qualified Ayurvedic practitioner or your doctor before taking any herb.

Why is guggulu an endangered-species concern?

Its source tree, C. wightii, was moved to Critically Endangered on the IUCN Red List because of destructive resin tapping (Yang et al.).

Sources

• Sarup P, Bala S, Kamboj S. "Pharmacology and Phytochemistry of Oleo-Gum Resin of Commiphora wightii (Guggulu)." Scientifica. 2015 — onlinelibrary.wiley.com
• Szapary PO, Wolfe ML, Bloedon LT, et al. "Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial." JAMA. 2003;290(6):765-772 — PubMed · PMID 12915429
• Brobst DE, Ding X, Lichti K, et al. "Pregnane X receptor and natural products: beyond drug-drug interactions." Expert Opin Drug Metab Toxicol. 2006 — PMC · PMC2978027
• "Guggulipid and rhabdomyolysis." Medscape review (case-report corroboration) — medscape.com
• Yang Y, Sun X, Peng C, et al. "The Genus Commiphora: An Overview of Its Traditional Uses, Phytochemistry, Pharmacology, and Quality Control." Pharmaceuticals. 2024 — PMC · PMC11597752

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.